REGN (Regeneron Pharmaceuticals) Price-to-Operating-Cash-Flow : 15.06 (As of Jun. 30, 2025)

View and export this data going back to 1991. Start your Free Trial

What is Regeneron Pharmaceuticals Price-to-Operating-Cash-Flow?

As of today (2025-06-30), Regeneron Pharmaceuticals's share price is $522.50. Regeneron Pharmaceuticals's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 was $34.69. Hence, Regeneron Pharmaceuticals's Price-to-Operating-Cash-Flow Ratio for today is 15.06.

The historical rank and industry rank for Regeneron Pharmaceuticals's Price-to-Operating-Cash-Flow or its related term are showing as below:

REGN' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.61 Med: 22.35 Max: 129.08
Current: 15.03

During the past 13 years, Regeneron Pharmaceuticals's highest Price-to-Operating-Cash-Flow Ratio was 129.08. The lowest was 7.61. And the median was 22.35.

REGN's Price-to-Operating-Cash-Flow is ranked better than
68.65% of 303 companies
in the Biotechnology industry
Industry Median: 24.72 vs REGN: 15.03

Regeneron Pharmaceuticals's Cash Flow from Operations per share for the three months ended in Mar. 2025 was $9.40. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 was $34.69.

During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Regeneron Pharmaceuticals was -16.50% per year. During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -15.30% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 13.20% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 21.20% per year.

During the past 13 years, Regeneron Pharmaceuticals's highest 3-Year average Operating Cash Flow per Share Growth Rate was 64.10% per year. The lowest was -80.30% per year. And the median was 20.40% per year.

Regeneron Pharmaceuticals Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Regeneron Pharmaceuticals's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Price-to-Operating-Cash-Flow Chart

Regeneron Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

21.24

10.01

16.33

21.74

18.55

Regeneron Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial															23.18	29.51	28.49	18.55	18.28

Competitive Comparison of Regeneron Pharmaceuticals's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Regeneron Pharmaceuticals's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regeneron Pharmaceuticals's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Regeneron Pharmaceuticals's Price-to-Operating-Cash-Flow falls into.

Save Embed

;

Save Embed

;

Regeneron Pharmaceuticals Price-to-Operating-Cash-Flow Calculation

Regeneron Pharmaceuticals's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	522.50	/	34.694
	=	15.06

Regeneron Pharmaceuticals's Share Price of today is $522.50.
Regeneron Pharmaceuticals's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $34.69.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Regeneron Pharmaceuticals Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Regeneron Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (NAS:REGN) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

REGN:Mexico 0R2M:UK RGO:Germany RGO:Germany REGN34:Brazil REGN:Austria

Address

777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707

Website

https://www.regeneron.com

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Executives

Marion Mccourt	officer: SVP Commercial	C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Arthur F Ryan	director	CITIZENS FINANCIAL GROUP, INC, 600 WASHINGTON BOULEVARD, STAMFORD CT 06901
Christopher R. Fenimore	officer: VP, Controller	REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Bonnie L Bassler	director	REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Christine A Poon	director	C/O JOHNSON & JOHNSON, ONE JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Andrew J Murphy	officer: EVP Research	REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Neil Stahl	officer: SVP, Preclinical Development	777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Joseph J Larosa	officer: SVP Gen Counsel & Secretary	777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Michael S Brown	director
Leonard S Schleifer	director, officer: President & CEO	777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
George Yancopoulos	director, officer: President and CSO	777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
George L Sing	director	LANCET CAPITAL, 45 ROCKEFELLER PLAZA STE 2008, NEW YORK NY 10111
Van Plew Daniel P	officer: EVP & General Mgr Industrial O	REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Joseph L Goldstein	director	DEPT OF PHARMACOLOGY K5 YUVER OF TEXAS, 5323 HARRY HINES BLVD, DALLAS TX 75390
Huda Y Zoghbi	director	REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591